证券日报网讯 2月11日，复星医药在互动平台回答投资者提问时表示，复宏汉霖是公司的控股子公司， 其收入全额纳入公司合并报表范围。创新药品收入方面，2025年公司前三季度创新药品收入超人民币67 亿元，较上年同期增长18.09%，并呈现稳健增长态势。随着2025年复迈宁、复妥宁、万缇乐、普瑞尼 等产品新获纳入国家医保目录以及奕凯达新获纳入商保创新药品目录，公司创新药品有望进一步扩大市 场覆盖、为收入提供增量。此外，公司创新管线临床开发的持续推进，也有望为后续年度公司创新药品 收入的增长提供新的动力。 （文章来源：证券日报） ...

Core Insights - The company reflects on a year of significant achievements in the biopharmaceutical sector, highlighting the successful clinical use of its innovative drug, Revamin, and the approval of multiple CAR-T products, showcasing its commitment to addressing rare diseases and cancer treatment gaps [3][6][33] - Club Med has seen substantial growth, with global revenue projected to increase from €1.5 billion in 2015 to €2.1 billion in 2024, and operating profit has grown over five times, indicating strong market demand for innovative travel experiences [9][40] - The company emphasizes its focus on user-centered product development in the tourism sector, aiming to enhance family vacation experiences rather than merely creating tourist attractions [6][38] Biopharmaceutical Innovations - Revamin has been officially launched for clinical use, filling a treatment void for rare tumors in China [3][7] - The company has successfully developed and received approval for multiple innovative drugs, including the first CAR-T product for gastric cancer, which has been recognized as a breakthrough therapy [6][38] - Since 2019, the company has launched a total of 12 innovative drugs, demonstrating its ongoing commitment to patient care and treatment advancements [3][33] Tourism and Leisure Sector - Club Med's performance has reached new heights, with an increasing number of families prioritizing snow vacations, supported by the ongoing development of the "Super Mediterranean" project [6][38] - The company has introduced three core product lines in the tourism sector, focusing on user needs to enhance vacation experiences [6][38] - Atlantis in Sanya has solidified its leading position in the vacation market, with annual visitor numbers reaching 1.5 million [11][43] Globalization and Market Expansion - The company has achieved over 50% of its revenue from international markets, highlighting its successful globalization strategy [16][45] - The Portuguese insurance subsidiary has seen nearly 30% of its business come from international operations, contributing to a diversified revenue stream [16][45] - The company has established strategic partnerships, such as with Fakeeh Care Group in Saudi Arabia, to expand its CAR-T technology internationally [16][46] Cultural and Community Engagement - The company has actively engaged in cultural initiatives, such as the successful summer event at Yuyuan Garden, attracting over 7.5 million visitors, with a significant portion being young people [52] - The company has been recognized for its commitment to social responsibility, being included in the S&P Global Sustainability Yearbook for the second consecutive year [54] - Ongoing support for educational and healthcare initiatives, including donations to Fudan University Affiliated Hospital, reflects the company's dedication to community welfare [57]

Core Insights - The World Intellectual Property Organization (WIPO) has reported that China has successfully risen to the top ten in the Global Innovation Index, highlighting significant progress in technology research and innovation ecosystem development [1] - The upcoming 20th Central Committee meeting is expected to focus on innovation as a key direction for the 14th Five-Year Plan, increasing market attention on companies' technological innovations and strategies [1] Group 1: Company Performance - Fosun International has demonstrated steady revenue and profit growth driven by its core capabilities in innovation and globalization, with a recommendation to "buy" from multiple brokerages [1][2] - The company has made breakthroughs in innovative drugs, including HLX43, a PD-L1 antibody-drug conjugate currently undergoing clinical trials in several countries, positioning it as a potential effective cancer treatment [2] Group 2: Globalization Strategy - Fosun has built a global research, registration, and marketing capability over the past decade, with its biopharmaceutical products reaching nearly 60 countries and benefiting over 850,000 patients [3] - The company’s core product for breast cancer treatment, Hanquyou, has been approved in over 50 countries, showcasing its global reach [3] Group 3: Technological Innovation - Fosun is embracing AI applications across its business sectors, with significant growth in its tourism segment, where the core area of Yuyuan Mall achieved a GMV of RMB 2.6 billion, a 55% year-on-year increase [3] - In the tourism sector, Fosun's Club Med is enhancing its digital services through AI, providing personalized 24/7 support across multiple countries [4] Group 4: Financial Strength - The company has shown robust financing capabilities and an optimized financial structure, with several brokerages expressing confidence in its financial health [5] - In September, Fosun secured a sustainable syndicated loan of $910 million, setting a record for offshore loans for private enterprises in 2025, reflecting strong market confidence in its future [5]

Core Insights - The World Intellectual Property Organization (WIPO) has reported that China has successfully risen to the top ten in the global innovation index, highlighting significant progress in technology research and innovation ecosystem development [1] - The upcoming 20th Central Committee meeting is expected to focus on innovation as a key direction for the 14th Five-Year Plan, increasing market attention on companies' technological innovations and strategies [1] Group 1: Company Performance - Fosun International has demonstrated steady revenue and profit growth driven by its core capabilities in innovation and globalization, with a positive outlook from multiple securities firms [1][2] - The company has received "buy" or "hold" ratings from various institutions, with target prices ranging from 6.5 to 7.5 HKD [1] Group 2: Innovation and Drug Development - Fosun has made significant advancements in its health sector, with innovative drugs like HLX43, a PD-L1 antibody-drug conjugate, undergoing clinical trials in multiple countries [2] - The company has also achieved breakthroughs with its self-developed targeted drug, Fumainin, which has been approved for rare disease indications, filling treatment gaps in oncology [2] Group 3: Globalization Strategy - Fosun has built a global research, registration, and marketing capability over the past decade, with its biopharmaceutical products reaching nearly 60 countries and benefiting over 850,000 patients [3] - The company has established a leading platform for small molecule innovation and has completed over 800 regulatory applications globally, with more than 600 approvals [3] Group 4: AI and Digital Transformation - Fosun is leveraging AI across various business sectors, enhancing customer experiences in tourism and improving operational efficiency in insurance [4] - The company has partnered with Alibaba Cloud to develop an AI-driven tourism assistant, significantly enhancing customer service capabilities [4] Group 5: Financial Strength and Capital Operations - Fosun has shown robust financing capabilities and an optimized financial structure, with a recent syndicate loan agreement reaching a record high of 9.1 billion USD equivalent [5] - The company is expected to continue optimizing its asset structure following recent interest rate cuts by the Federal Reserve, maintaining financial stability [5]

Core Insights - The 2025 Sustainable Global Leaders Conference was held in Shanghai, focusing on global action, innovation, and sustainable growth, with around 500 attendees including Nobel laureates and leaders from Fortune 500 companies [1] Group 1: Innovation and Globalization - Fosun International's co-chairman, Wang Qunbin, emphasized the company's commitment to innovation as a core driver for achieving both commercial and social value [3] - Fosun has developed the H drug, the first PD-1 monoclonal antibody approved for first-line treatment of small cell lung cancer, which has been approved in nearly 40 countries, benefiting over 110,000 patients globally [4][5] - The company is also advancing other innovative drugs, such as HLX43, a PD-L1 antibody-drug conjugate, which has the potential to become a broad-spectrum anti-cancer drug [5] Group 2: Global Reach and Market Integration - Fosun has established a global presence in over 40 countries, focusing on integrating innovation capabilities with value chain management [6] - The company has built a global R&D and marketing capability, with its biopharmaceutical products reaching nearly 60 countries and benefiting over 850,000 patients [6] - In the financial services sector, Fosun's insurance operations in Portugal have improved efficiency through AI applications, increasing auto insurance claim approval rates from 48% to 66% [7] Group 3: Corporate Social Responsibility and ESG - Fosun has prioritized ESG responsibilities, contributing to global malaria control by supplying over 420 million doses of injectable artemisinin [8][9] - The company has initiated a rural doctor project in China, covering 78 counties and benefiting over 16 million rural residents [9] - Fosun maintains an AA rating in MSCI ESG ratings and is recognized in the top 1% of Chinese companies in the S&P Global Sustainable Development Yearbook [9] Group 4: Future Vision - Wang Qunbin stated that the power of business for good is driving profound changes in corporate and societal relationships, with Fosun aiming to continue its sustainable development journey through innovation and responsibility [10]

Core Viewpoint - The 2025 Sustainable Global Leaders Conference held in Shanghai emphasizes global action, innovation, and sustainable growth, featuring around 500 attendees including Nobel Prize winners and leaders from Fortune 500 companies [1] Group 1: Innovation and Globalization - Fosun International's co-chairman, Wang Qunbin, highlighted the company's journey of globalization driven by innovation, aiming for a win-win in commercial and social value [3] - Fosun has developed the first approved anti-PD-1 monoclonal antibody, H drug, for the treatment of extensive-stage small cell lung cancer, which has been approved in nearly 40 countries, benefiting over 110,000 patients globally [4][5] - The company is transitioning from "following" to "leading" in the innovative drug sector, focusing on unmet clinical needs and global partnerships to advance healthcare [5] Group 2: Global Value Creation - Fosun has established a global presence in over 40 countries, building capabilities in research, registration, business development, and marketing, with its innovative biopharmaceutical products reaching nearly 600,000 patients [6] - The company has achieved significant growth in business development contracts, with cash inflow exceeding 1 billion yuan, a 280% increase year-on-year [6] - In the tourism sector, Fosun is enhancing customer experience through AI digital upgrades, expanding its services across 12 countries [6] Group 3: Corporate Social Responsibility - Fosun emphasizes the importance of ESG (Environmental, Social, Governance) responsibilities, contributing to global malaria control by supplying over 420 million doses of artemisinin-based injections [8][9] - The company has initiated a rural doctor project in China, benefiting 3 million rural families and over 16 million rural residents [9] - Fosun maintains a strong MSCI ESG rating of AA and is recognized in the top 1% of Chinese companies for sustainability efforts [9][10] Group 4: Future Vision - Wang Qunbin stated that the power of business for good is driving profound changes in the relationship between enterprises and society, and Fosun aims to continue climbing new heights in sustainable development [10]